STEVEN HERBERT ABMAN

Summary

Affiliation: University of Colorado Denver
Country: USA

Publications

  1. doi request reprint Pulmonary hypertension in children: a historical overview
    Steven H Abman
    Department of Pediatrics, Pediatric Heart Lung Center, University of Colorado School of Medicine, and The Children s Hospital, Aurora, CO, USA
    Pediatr Crit Care Med 11:S4-9. 2010
  2. ncbi request reprint Inhaled nitric oxide for the treatment of pulmonary arterial hypertension
    Steven H Abman
    University of Colorado School of Medicine, Aurora, CO, USA
    Handb Exp Pharmacol 218:257-76. 2013
  3. doi request reprint Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension
    Steven H Abman
    Department of Pediatrics, Pediatric Pulmonary Hypertension Network, University of Colorado School of Medicine, 13123 East 16th Avenue, Aurora, CO 80045, USA
    Am J Respir Crit Care Med 187:572-5. 2013
  4. pmc Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension
    Marc Chester
    Pediatric Heart Lung Center, Sections of Neonatology and Pulmonary Medicine, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA
    Am J Physiol Lung Cell Mol Physiol 301:L755-64. 2011

Research Grants

Collaborators

Detail Information

Publications4

  1. doi request reprint Pulmonary hypertension in children: a historical overview
    Steven H Abman
    Department of Pediatrics, Pediatric Heart Lung Center, University of Colorado School of Medicine, and The Children s Hospital, Aurora, CO, USA
    Pediatr Crit Care Med 11:S4-9. 2010
    ....
  2. ncbi request reprint Inhaled nitric oxide for the treatment of pulmonary arterial hypertension
    Steven H Abman
    University of Colorado School of Medicine, Aurora, CO, USA
    Handb Exp Pharmacol 218:257-76. 2013
    ..This review will describe the current use of inhaled NO in clinical practice and briefly discuss its potential role for the treatment of chronic PAH. ..
  3. doi request reprint Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension
    Steven H Abman
    Department of Pediatrics, Pediatric Pulmonary Hypertension Network, University of Colorado School of Medicine, 13123 East 16th Avenue, Aurora, CO 80045, USA
    Am J Respir Crit Care Med 187:572-5. 2013
    ..Pediatric patients with PAH require close surveillance and frequent monitoring, and persistent sildenafil monotherapy is likely insufficient with disease progression...
  4. pmc Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension
    Marc Chester
    Pediatric Heart Lung Center, Sections of Neonatology and Pulmonary Medicine, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA
    Am J Physiol Lung Cell Mol Physiol 301:L755-64. 2011
    ..We speculate that increased NO-insensitive sGC may contribute to the pathogenesis of PPHN, and cinaciguat may provide a novel treatment of severe pulmonary hypertension...

Research Grants11

  1. Role of VEGF in Perinatal Pulmonary Hypertension
    STEVEN HERBERT ABMAN; Fiscal Year: 2010
    ....
  2. Role of VEGF in Perinatal Pulmonary Hypertension
    STEVEN ABMAN; Fiscal Year: 2009
    ....
  3. Role of VEGF in Perinatal Pulmonary Hypertension
    STEVEN ABMAN; Fiscal Year: 2004
    ..Studies will utilize the chronically-prepared fetal lamb model to provide an integrative physiologic approach that combines whole animal physiology with molecular, biochemical, and morphometric studies. ..
  4. Role of VEGF in Perinatal Pulmonary Hypertension
    STEVEN ABMAN; Fiscal Year: 2001
    ..Studies will utilize the chronically-prepared fetal lamb model to provide an integrative physiologic approach that combines whole animal physiology with molecular, biochemical, and morphometric studies. ..
  5. Genetic Basis for Impaired Angiogenic Signaling in BPD
    STEVEN ABMAN; Fiscal Year: 2009
    ....
  6. Role of VEGF in Perinatal Pulmonary Hypertension
    STEVEN ABMAN; Fiscal Year: 2007
    ....
  7. Role of VEGF in Perinatal Pulmonary Hypertension
    STEVEN ABMAN; Fiscal Year: 2003
    ..Studies will utilize the chronically-prepared fetal lamb model to provide an integrative physiologic approach that combines whole animal physiology with molecular, biochemical, and morphometric studies. ..
  8. Role of VEGF in Perinatal Pulmonary Hypertension
    STEVEN ABMAN; Fiscal Year: 2002
    ..Studies will utilize the chronically-prepared fetal lamb model to provide an integrative physiologic approach that combines whole animal physiology with molecular, biochemical, and morphometric studies. ..
  9. Genetic Basis for Impaired Angiogenic Signaling in BPD
    STEVEN HERBERT ABMAN; Fiscal Year: 2010
    ....